Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Matulonis, Ursula
Item TypeName
Academic Article A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.
Academic Article Comparison of the quality of life of early and advanced stage ovarian cancer survivors.
Academic Article A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.
Academic Article Rational use of cytotoxic chemotherapy for recurrent ovarian cancer.
Academic Article Long-term adjustment of early-stage ovarian cancer survivors.
Academic Article A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
Academic Article Ovarian cancer clinical practice guidelines.
Academic Article Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.
Academic Article Bevacizumab and its use in epithelial ovarian cancer.
Academic Article Ovarian cancer, version 3.2012.
Academic Article Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
Academic Article Anti-angiogenic agents in ovarian cancer: dawn of a new era?
Academic Article Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Academic Article ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
Academic Article The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
Academic Article Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Academic Article New advances in ovarian cancer.
Academic Article A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
Academic Article Bevacizumab rechallenge after first line maintenance bevacizumab.
Academic Article A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors.
Academic Article Attitudes to chemotherapy in patients with ovarian cancer.
Academic Article Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Academic Article Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Academic Article Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Academic Article Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
Concept Neoplasm Recurrence, Local
Concept Recurrence
Academic Article Hopelessness and complementary therapy use in patients with ovarian cancer.
Academic Article A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Academic Article Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.
Academic Article Ovarian cancer, version 2.2013.
Academic Article Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Academic Article ß-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers.
Academic Article A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Academic Article Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Academic Article Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Academic Article Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Academic Article Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
Academic Article Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
Academic Article Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
Academic Article Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.
Academic Article Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Academic Article Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
Academic Article Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Academic Article Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Academic Article Niraparib in Recurrent Ovarian Cancer.
Academic Article Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Academic Article Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Academic Article Safety and dose modification for patients receiving niraparib.
Academic Article PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
Academic Article Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Academic Article Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Academic Article Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Academic Article Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Academic Article Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Academic Article A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Academic Article Efficacy and safety of niraparib as maintenance treatment in older patients (=?70?years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Academic Article Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.
Academic Article Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Academic Article Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Academic Article Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Academic Article Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.
Academic Article Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Search Criteria
  • Recurrence
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.